Rimegepant yog ib qho me me molecule inhibitor ntawm covcalcitoningene-related peptide (CGRP) receptor uas thaiv qhov kev ua ntawm CGRP, lub zog vasodilator ntseeg tau ua lub luag haujlwm hauv kev mob taub hau.Rimegepant tau pom zoo rau kev kho mob migraine mob.Hauv kev sim tshuaj, rimegepant feem ntau tau txais txiaj ntsig zoo nrog tsuas yog qee qhov tsis tshua muaj tshwm sim ntawm cov ntshav ntshav aminotransferase nce siab thaum lub sijhawm kho thiab tsis muaj qhov tshwm sim ntawm kev mob siab rau lub siab.

Rimegepant yog tus tiv thaiv qhov ncauj ntawm CGRP receptor tsim los ntawm Biohaven Pharmaceuticals.Nws tau txais kev pom zoo los ntawm FDA thaum Lub Ob Hlis 27, 2020 rau kev kho mob taub hau migraine.Txawm hais tias ntau tus parenteral antagonists ntawm CGRP thiab nws cov receptor tau pom zoo rau kev kho mob migraine (xws li [erenumab], [fremanezumab], [galcanezumab]), rimegepant thiab [ubrogepant] tsuas yog cov tswv cuab ntawm "gepants" tsev neeg ntawm cov tshuaj tseem tshuav hauv kev txhim kho, thiab tsuas yog CGRP antagonists uas muaj qhov ncauj bioavailability.Cov txheej txheem tam sim no ntawm kev kho mob migraine cuam tshuam nrog kev kho tus kheej nrog "triptans", xws li [sumatriptan], tab sis cov tshuaj no yog contraindicated nyob rau hauv cov neeg mob uas twb muaj lawm cerebrovascular thiab kab mob plawv vim lawv vasoconstrictive zog.Kev tawm tsam ntawm CGRP txoj hauv kev tau dhau los ua lub hom phiaj zoo rau kev kho mob migraine li, tsis zoo li triptans, qhov ncauj CGRP antagonists tsis tau pom cov khoom vasoconstrictive thiab yog li muaj kev nyab xeeb dua rau kev siv rau cov neeg mob uas muaj contraindications rau kev kho tus qauv.

Rimegepant yog ibCalcitoninGene-related Peptide Receptor Antagonist.Lub mechanism ntawm kev txiav txim ntawm rimegepant yog raws li ib tugCalcitoninGene-related Peptide Receptor Antagonist.